Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00113815 · ClinicalTrials.gov registry record · Phase 3
Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures
A Phase 3 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 3
- Development phase
- 118
- Enrollment target
NCT00113815 is a Phase 3 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 118 participants.
The verdict
NCT00113815, a Phase 3 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 118 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the tolerability, safety and efficacy of topiramate in infants with refractory partial onset seizures (POS).
Interventions
- DRUG placebo
- DRUG topiramate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2005-05 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00113815
The ClinicalTrials.gov registry entry for NCT00113815 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00113815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00113815 about?
NCT00113815 is a clinical study titled "Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures". The purpose of this study is to evaluate the tolerability, safety and efficacy of topiramate in infants with refractory partial onset seizures (POS).
What is the current status of trial NCT00113815?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 118 participants. The study started on 2005-05. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00113815?
The interventions under investigation include: placebo (DRUG), topiramate (DRUG).
Who is sponsoring clinical trial NCT00113815?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.